Nazol (Naphazoline Nitrate)

Naphazoline nitrate selectively stimulates alpha‑adrenergic receptors on the blood vessels of the nasal lining. This causes vasoconstriction, which decreases blood flow, reduces edema, and opens the nasal passages for easier breathing.

The appropriate dose of Nazol is determined by a qualified healthcare professional. Typical adult dosing involves one or two sprays per nostril, not to exceed the recommended maximum duration of three to five days, but exact instructions should follow the prescriber’s order.

Safety data for naphazoline nitrate during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their physician before using Nazol.

To place an order, submit an enquiry on the Nazol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nazol’s active ingredient, naphazoline nitrate, has a rapid onset similar to oxymetazoline but may have a slightly higher risk of rebound congestion if used beyond the recommended period. Both belong to the alpha‑adrenergic agonist class, yet individual tolerance and local irritation profiles can differ.

Nazol should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and keep it out of reach of children.

Nazol is applied topically to the nasal mucosa. The user tilts the head slightly forward, inserts the spray tip into one nostril, and delivers the prescribed number of sprays. The same procedure is repeated for the other nostril if required.

Serious risks include severe hypertension, cardiac arrhythmias, allergic reactions such as anaphylaxis, and nasal ulceration or perforation. Prolonged use can also cause rebound congestion (rhinitis medicamentosa), which may worsen nasal blockage.

Nazol should be avoided by individuals with known hypersensitivity to naphazoline nitrate, by patients taking monoamine oxidase inhibitors, and by those with uncontrolled hypertension, severe coronary artery disease, or recent eye surgery involving the nasal passages.